Cagrilintide
Stocked in 5mg, 10mg, 20mg at MontanaPep in Great Falls, Montana. Sold for laboratory research use only.
| Size | Catalog no. | Price per vial |
|---|---|---|
| 5mg | CGL5 | $45 |
| 10mg | CGL10 | $50 |
| 20mg | CGL20 | $85 |
Classification
Synthetic long-acting amylin analogue
Structure and chemistry
Cagrilintide is a modified analogue of human amylin engineered for stability and a long half-life. Amylin itself is prone to forming amyloid fibrils, which historically made it a difficult drug-design target; cagrilintide’s published development used amino-acid substitution together with a fatty-acid side chain for reversible albumin binding, the same half-life-extension approach used for semaglutide.
What the published research shows
Published research includes the medicinal-chemistry program describing cagrilintide’s design and selection, cryo-electron-microscopy structural work on how it engages amylin and calcitonin receptors, and a clinical-trial record spanning Phase 1 through Phase 3 in obesity, both as a standalone agent and in combination with semaglutide (studied together as “CagriSema”).
Mechanism of action
An amylin-receptor agonist. Amylin is a pancreatic hormone co-secreted with insulin that contributes to satiety and slows gastric emptying; cagrilintide is designed to reproduce and extend those effects, with a half-life long enough for once-weekly administration in clinical studies.
Development history
Developed at Novo Nordisk following the amylin analogue pramlintide, which requires three daily injections because native amylin is short-lived and prone to aggregation in solution. The medicinal-chemistry paper describing cagrilintide’s development was published in 2021.
Current regulatory status
Cagrilintide is an investigational compound; it is not an FDA-approved medicine as a standalone agent. Clinical development has continued through Phase 3 obesity trials, both alone and combined with semaglutide, with regulatory decisions pending as of this reference update.
Analytical testing
Identity and purity should be evaluated with methods appropriate to the claimed material, such as HPLC and mass spectrometry. HPLC area percentage alone does not establish molecular identity or net peptide content.
Ordering from Great Falls
MontanaPep, also known as Montana Peptides, is an independently owned supplier based at 715 13th Ave S, Great Falls, Montana. Local pickup is available by arrangement, and we ship to research addresses across Montana including Billings, Missoula, Bozeman, Helena, Butte, Kalispell and Havre. Call (406) 799-0812 or email customerservice@montanapep.com.